Levetiracetam

If you take levetiracetam (brand name Keppra) for seizures, this test measures the drug's concentration in your serum. It can help explain a change in treatment response during pregnancy, kidney disease, a medication change, or the return of seizures on a dose that used to work.

This is an established test for monitoring medication in selected situations, but no single concentration reliably separates effective treatment from treatment failure or side effects. Your seizure history, symptoms, prescribed dose, and earlier results all matter.

What the Level Measures

Serum is the liquid left after blood clots. This test reports the concentration of unchanged levetiracetam in serum, including both freely circulating drug and drug attached to proteins. Results are reported in µg/mL. Less than 10% attaches to blood proteins, so most circulating levetiracetam is unbound.

Laboratory and animal research links the drug's antiseizure effects to its binding to a nerve-cell protein called SV2A. That protein helps regulate the release of chemical messages between nerve cells. The full mechanism by which levetiracetam prevents seizures in people remains incompletely understood.

About two-thirds of a dose leaves your body unchanged in urine. Another portion is broken down into inactive products through processes that depend little on the liver enzymes responsible for many drug interactions. Your kidneys therefore have a large influence on how much drug remains in circulation.

In adults with normal kidney function, the circulating amount falls by about half over 6 to 8 hours. Levels rise after a dose and fall between doses. A trough is the lowest concentration before the next scheduled dose, and sampling time affects how a result can be interpreted.

Seizure Control and Your Level

People taking similar doses can have very different concentrations. A Korean study of serum trough samples from 550 people found wide variation, with about 30% of analyzed samples below the laboratory's reference interval. That finding alone doesn't establish whether treatment was failing.

The reverse problem also occurs: seizures can continue despite a result inside a laboratory interval. A real-world study of plasma monitoring across several newer seizure medicines found that samples drawn because seizures were poorly controlled often fell inside their drug-specific intervals. Those were mixed-drug plasma findings, so they cannot establish a threshold for this levetiracetam serum test.

Evidence also differs by setting and seizure type. A retrospective study of 1,174 children used plasma concentrations and found an association between concentration and response only in focal epilepsy. Focal seizures start in one area of the brain. A smaller study of serum levels in 50 children with difficult-to-treat epilepsy found no clear relationship with seizure reduction or side effects. Neither study established a concentration that guarantees seizure control.

Pregnancy and the Weeks After Birth

Pregnancy can substantially lower levetiracetam concentrations at the same dose. Kidney filtration increases, and the amount of fluid through which the drug distributes changes. Serum studies have documented declines as early as the first trimester, although the size and timing of the change vary.

A study of 29 pregnancies combined venous samples with calibrated dried blood spot measurements. Lower concentrations were associated with worsening seizures in the subgroup that had experienced seizures during the year before pregnancy. The association wasn't statistically clear in the previously seizure-free subgroup. This small study wasn't restricted to serum samples and doesn't establish that a fall is harmless if you were seizure-free before conception.

After delivery, the body can begin clearing the drug more slowly within days. Concentrations may rise quickly when a pregnancy-related dose increase is still in place. This change is relevant even if the pregnancy itself passed without a seizure.

Monitoring has a clear biological rationale, but its effect on seizure outcomes is less certain. The EMPiRE trial randomized 263 women after their antiseizure medication concentration fell by at least a quarter. Providing monthly results to guide treatment didn't significantly improve the time to a first seizure compared with treatment guided by clinical features. The trial included several medicines and recruited fewer women than planned, so it doesn't give a definitive answer for levetiracetam alone.

The drug crosses the placenta and enters breast milk. Small studies found concentrations in cord blood and milk similar to maternal concentrations, while breastfed infants usually had much lower blood concentrations. Low infant concentrations should not be attributed to unusually fast newborn clearance: a study using plasma samples found that newborns eliminated the drug more slowly than adults.

Kidney Function, Age, and Intensive Care

When kidney function declines, levetiracetam can accumulate at an unchanged dose. This is one reason older adults may need lower doses. Age alone doesn't determine the concentration; kidney function and the dose being taken matter more.

Some people with major trauma or brain injury develop unusually fast kidney filtration during intensive care. This is called augmented renal clearance. Small studies measuring plasma concentrations found that such patients could remove levetiracetam rapidly and have lower exposure than expected. These plasma findings support the biological explanation, but their numerical targets shouldn't be transferred directly to an outpatient serum result.

Beyond the newborn period, children generally clear more levetiracetam per kilogram of body weight than adults. Growth and kidney development affect dosing, which is why an adult dose or concentration cannot be applied to a child without considering age, weight, and treatment response.

Checking Whether Doses Are Being Taken

A result can contribute to a discussion about missed doses. An unexpectedly low concentration may reflect missed medication, but it can also reflect sampling time, faster clearance, or a dose that produces a low concentration for that person. A single result cannot prove how consistently you've taken the medicine over previous weeks.

When Results Can Be Misleading

• Different sampling times: a sample taken after a dose and a sample taken just before the next dose represent different points in the dosing cycle. Comparing them without accounting for timing can create an apparent change.
• Delayed serum separation: levetiracetam can continue breaking down while blood remains unseparated. In a sample-handling study, concentrations in whole blood kept at room temperature fell by 11% after 2 days and 29% after 7 days, while separated serum remained stable over that period.
• A recent dose change or irregular dosing: the concentration may not represent the pattern expected after repeated doses on a stable schedule.
• Food and absorption timing: food can delay absorption of immediate-release levetiracetam without reducing the total amount absorbed. This matters more for samples taken near a dose than for consistently timed trough samples.
• A different laboratory or specimen: methods and sample preparation can differ. Plasma, serum, saliva, and dried blood spot results require the validation and interpretation appropriate to their own specimen and method.
• Overreading a laboratory flag: a result inside a laboratory interval doesn't rule out side effects, and a result outside it doesn't by itself establish treatment failure or toxicity.

Tracking Your Trend

A concentration documented during good seizure control and acceptable side effects provides a useful personal comparison. A later change can help explain altered drug exposure, especially if the dose and sampling time are comparable. That earlier concentration isn't a permanent guarantee of control: epilepsy can change, and seizures can recur without a fall in the drug level.

Routine testing at every visit hasn't shown a clear advantage. In a randomized trial of 151 adults starting or adjusting newer seizure medicines, scheduled plasma monitoring didn't improve treatment efficacy or tolerability compared with testing triggered by treatment problems. The trial included levetiracetam among several medicines; it wasn't a trial of this serum test alone. Selective monitoring remains useful when there is a specific question about exposure.